AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02749136
Drug: Preoperative modified FOLFIRINOX and postoperative gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles~  * Oxaliplatin IV 85 mg/m2 Day (D) 1~ * Irinotecan IV 180 mg/m2 D1~ * 5-FU continuous IV infusion 2,400 mg/m2 over 46 hours D1-2~ * Leucovorin IV 400 mg/m2 D1~* Postoperative gemcitabine, every 4 weeks, 3-6 cycles - Gemcitabine 1,000 mg/ m2 D1, 8, and 15
Trial: NCT03039543
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2) neuromuscular blockade for patients with moderate neuromuscular blockade whereas intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade for patients with deep neuromuscular blockade.
Trial: NCT03039543
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2 and patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
Trial: NCT02583568
Drug: Bevacizumab-800CW
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: three days prior to surgery bevacizumab-800CW will be administered
Trial: NCT00485056
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 45mgs daily
Trial: NCT02792647
Drug: IX-01
RxNorm normalized name: Hematoporphyrin ix
DrugBank: Hemoporfin (DB16183)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00104637
Drug: sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sildenafil citrate 25 mg by mouth thrice daily (po tid)
Trial: NCT01313624
Drug: AZLI
RxNorm normalized name: Bazlitoran
DrugBank: Bazlitoran (DB14990)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
Trial: NCT04510402
Drug: Povidine iodine nasal swabs
RxNorm normalized name: povidone-iodine Topical Ointment [Povidine]
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily versus twice daily nasal application
Trial: NCT01598207
Drug: Marinol
RxNorm normalized name: Marinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg BID, orally for 1 month
Trial: NCT01461824
Drug: Depot medroxyprogesterone acetate (DMPA)
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 75mg, 104mg and 150mg DMPA, IM, every 12 weeks for 12 months
Trial: NCT01689766
Drug: Technetium Tc 99m EC20
RxNorm normalized name: TECHNETIUM (Tc 99m)
DrugBank: Technetium Tc-99m (DB14227)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00715013
Drug: Patupilone
RxNorm normalized name: Patupilone
DrugBank: Patupilone (DB03010)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patupilone
Trial: NCT02580240
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vials containing normal saline as placebo were identical to those containing hydrocortisone. Placebo administration procedures were similar.
Trial: NCT03622541
Drug: Sorafenib 200mg
RxNorm normalized name: SORAFENIB 200MG TAB
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib is a multi-kinase inhibitor which is FDA approved for the treatment of metastatic hepatocellular and renal cell carcinomas.
Trial: NCT04111523
Drug: SY-007
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of SY-007 or placebo injection(1mg-45mg)
Trial: NCT02207439
Drug: Nelfinavir (Viracept®) 1250 mg
RxNorm normalized name: nelfinavir 250 MG [Viracept]
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Period 1: Nelfinavir Lead-In (1250 mg bid, 7-14 days).
Trial: NCT01832103
Drug: MK-7145
RxNorm normalized name: MK-7145
DrugBank: MK-7145 (DB11968)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00676156
Drug: oral lipoic acid (LA)
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 1200 mg dose of oral LA will be administered.
Trial: NCT00676156
Drug: lipoic acid (LA) with fish oil and LA without fish oil
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to receive either 1 dose of 1200 mg LA with fish oil and then will be crossed-over to receive 1 dose of 1200 LA without fish oil. There will be a 1-week wash out period between the cross over.
Trial: NCT00676156
Drug: R lipoic acid
RxNorm normalized name: R-alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 1200mg R enantiomer LA will be administered.
Trial: NCT00367341
Drug: escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive treatment with escitalopram for 12 weeks.
Trial: NCT03655665
Drug: Ofloxacin otic solution
RxNorm normalized name: ofloxacin Otic Solution
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three drops of ofloxacin otic 0.3%. intra and post-operatively for 3 days post-surgery on one ear.
Trial: NCT00984438
Drug: BCNU Wafer
RxNorm normalized name: carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implantable during surgical resection into the tumor bed
Trial: NCT00984438
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV every 2 weeks for up to one year
Trial: NCT00984438
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV every 2 weeks for up to one year
Trial: NCT02420041
Drug: triamcinolone/lidocaine
RxNorm normalized name: triamcinolone/lidocaine 20 mg-20 mg/4 mL INJECTION VIAL (ML)
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01902498
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
Trial: NCT01902498
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
Trial: NCT01902498
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 162mg po twice daily x 7days or end of hospitalization. First dose administered on post op day 1.
Trial: NCT03049345
Drug: Methylene Blue 20 MG/ML
RxNorm normalized name: methylene blue 20 MG/ML
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see above
Trial: NCT01278615
Drug: Selumetinib
RxNorm normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02649361
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib p.o. qd
Trial: NCT00616330
Drug: butoconazole nitrate
RxNorm normalized name: Butoconazole Nitrate
DrugBank: Butoconazole (DB00639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: semi solid, single dose
Trial: NCT03040830
Drug: Progesterone 100 IM/day
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone IM 100 mg /day was started on day of egg retrieval in egg retrieval arm and on day of embryo transfer in the embryo transfer arm
Trial: NCT01073319
Drug: Rivastigmine
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will be randomized to rivastigmine (1.5 mg bid) for 6 days of each phase.
Trial: NCT01073319
Drug: Rivastigmine
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will be randomized to rivastigmine (3 mg bid) for 6 days of each phase.
Trial: NCT01906528
Drug: Mivacurium
RxNorm normalized name: Mivacurium
DrugBank: Mivacurium (DB01226)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Effect of Mivacurium in males vs females
Trial: NCT04054414
Drug: Normal Saline along with standard treatment
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
Trial: NCT01900574
Drug: Golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab will be administered subcutaneously. For participants weighing less than 45 kg, the dose of golimumab at Week 0 will be 90 mg/m2 (up to 200 mg) and 45 mg/m2 (up to 100 mg) at Weeks 2, 6, and 10. For participants weighing 45 kg or more, the dose of golimumab at Week 0 will be 200 mg and 100 mg at Weeks 2, 6, and 10. From Week 14, the dose of golimumab will be 45 mg/m2 and 100 mg, every 4 weeks for participants weighing less than 45 kg and 45 kg or more, respectively. From Week 18, participants weighing 45 kg or more have the option to administer golimumab at home after being properly trained. At Week 14 or at any time after, the participants have the option to decrease their dose of golimumab to 50 mg (weighing 45 kg or more) or 22.5 mg/square meter (less than 45 kg) at the discretion of the investigator. A single dose increase back to 100 mg or 45 mg/m2 is permitted based on the investigator's assessment of an increase in a participant's ulcerative colitis disease activity.
Trial: NCT00715117
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally for 16 weeks
Trial: NCT01240252
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: U100 Humulin at a rate of 80 mU/m\^2 surface area per minute one time over 4 hours
Trial: NCT01652859
Drug: Liposomal Amphotericin B
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01652859
Drug: AmBisome
RxNorm normalized name: AmBisome
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00519285
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 25 mg/ml solution~6 mg/kg, 1-hour IV on Day 1 of each 3-Week cycle
Trial: NCT00519285
Drug: Placebo (for aflibercept)
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sterile aqueous buffered solution identical to aflibercept~1-hour IV on Day 1 of each 3-Week cycle
Trial: NCT00129740
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg orally twice daily
Trial: NCT02312011
Drug: IONIS-DMPKRx
RxNorm normalized name: IONIS SOD1Rx
DrugBank: Tofersen (DB14782)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug
Trial: NCT00081939
Drug: Velcade
RxNorm normalized name: Velcade
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Two cycles of induction on days 1,4,8,11 at 1.0mg/m\^2. Two cycles of consolidation on days 1,4,8,11 at 1.0mg/m\^2. Maintenance year one 1.0mg/m\^2 1,4,8,11 q 28 days.
Trial: NCT00519285
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Marketed formulation~75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)
Trial: NCT00119262
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00119262
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00519285
Drug: Prednisone or Prednisolone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Marketed formulation~5 mg twice daily PO from day 1 continuously
Trial: NCT00081939
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two cycles of VDTPACE 200mg thal days 4-7(cycle 1)and days 1-4 cycle 2 interim Thal 50mg qd between VTDPACE cycles and between cycle 2 and transplant. Thal 100mg between transplants d/c 7 days prior to each transplant. Consolidation therapy cycles 3 and 4 VDTPACE 200mg days 1-4 both cycles. Interim maintenance to maintenance 100mg qd. Maintenance year 1 thal 100mg qd. Maintenance years 2 and 3 Thal 100mg qd.
Trial: NCT00003760
Drug: irofulven
RxNorm normalized name: Irofulven
DrugBank: Irofulven (DB05786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive 6-hydroxymethylacylfulvene (MGI 114) IV over 5 minutes on days 1-5. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for up to 1 year after therapy initiation.
Trial: NCT00001626
Drug: antithymocyte globulin
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antithymocyte globulin
Trial: NCT00001626
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclosporine
Trial: NCT04414631
Drug: Conestat alfa
RxNorm normalized name: conestat alfa
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Conestat alfa (8400 Units (U) followed by 4200 U every 8 hours, 9 administrations in total) will be administered as a slow intravenous injection (5-10 minutes) over a 72 hour period.
Trial: NCT02576327
Drug: Tropisetron
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron Hydrochloride Injection 5mg (Day 1-6)
Trial: NCT02576327
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone Sodium Phosphate Injection 10mg (Day 1-6)
Trial: NCT02576327
Drug: Aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant 125mg （Day1-2）, 80mg (Day 3-6)
Trial: NCT04567810
Drug: anti-SARS-CoV-2 IgY
RxNorm normalized name: Anti-SARS-CoV-2 IgY
DrugBank: Anti-SARS-CoV-2 IgY (DB16356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
Trial: NCT03434028
Drug: Early Vasopressors
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine will be used as preferred vasopressor and titrated to achieve mean arterial pressure (MAP) between 65 mmHg and 75 mmHg. Rescue fluids may be administered as 500ml boluses if predefined rescue criteria are met.
Trial: NCT02595606
Drug: 0.3% Sodium Hyaluronate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: five times per day for the intervention of eye drop
Trial: NCT00179699
Drug: CC-5013
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00179699
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03179943
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be administered atezolizumab intravenously on day 1 and day 22 of a 6 week cycle for the period of 8 cycles.
Trial: NCT03179943
Drug: Guadecitabine
RxNorm normalized name: Guadecitabine
DrugBank: Guadecitabine (DB11918)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guadecitabine will be administered subcutaneously on days 1 through 5 of the 6 week cycle for the period of 4 cycles
Trial: NCT01261143
Drug: BK-C-0701
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet, 8 weeks
Trial: NCT03047772
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine dose of Atorvastatin therapy
Trial: NCT03047772
Drug: Intensive Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive dose of Atorvastatin therapy
Trial: NCT03047772
Drug: Low dose BMMSC
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
Trial: NCT03047772
Drug: Middle dose BMMSC
RxNorm normalized name: wheat middlings extract
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
Trial: NCT03047772
Drug: High dose BMMSC
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
Trial: NCT03047772
Drug: Transplantation
RxNorm normalized name: Transplantation antigen
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
Trial: NCT00049998
Drug: topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04297072
Drug: Rivaroxaban (Xarelto, BAY-597939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Non-vitamin K antagonist oral anticoagulants (NOACs). The prescription of drug is at the discretion of physician following the routine clinical practice.
Trial: NCT02744339
Drug: Riociguat
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adempas up-titrated to max. 1.5mg TID
Trial: NCT00383409
Drug: multivitamins
RxNorm normalized name: MULTIVITAMINS
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02667886
Drug: X4P-001
RxNorm normalized name: CXCR4 INHIBITOR X4P-001
DrugBank: Mavorixafor (DB05501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous, oral dosing
Trial: NCT02667886
Drug: axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous, oral dosing
Trial: NCT00985270
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03391856
Drug: N-acetyl-L-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NAC treatment for PT: 400mg p.o tid from day 60 to 90 post transplant
Trial: NCT00509405
Drug: potassium citrate
RxNorm normalized name: Potassium Citrate
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6 times 10 mEq per day, oral for 24 months
Trial: NCT03455777
Drug: AKCEA-ANGPTL3-LRX
RxNorm normalized name: Akcea ttr lrx
DrugBank: Eplontersen (DB16199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single open-label cohort
Trial: NCT02484547
Drug: Aducanumab (BIIB037)
DrugBank: Aducanumab (DB12274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low dose
Trial: NCT02781311
Drug: Setipiprant
RxNorm normalized name: Setipiprant
DrugBank: Setipiprant (DB12562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setipiprant tablets, orally, BID for 24 weeks.
Trial: NCT02781311
Drug: Finasteride
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Finasteride tablet, orally, once daily for 24 weeks.
Trial: NCT01813305
Drug: CSTC1
RxNorm normalized name: Cortisone
DrugBank: Cortisone acetate (DB01380)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof
Trial: NCT02786836
Drug: 13C-Methacetin
RxNorm normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The test substrate in this study, ¹³C-methacetin solution for single-use oral administration (75 mg in 150 ml purified water), is administered orally or via feeding tube, rapidly absorbed, exclusively metabolized by hepatic mixed function oxidase via O-demethylation, mainly by cytochrome P450 enzyme, subtype 1A2, into acetaminophen and formaldehyde. The formaldehyde is then transformed through two successive oxidative steps to ¹³carbon dioxide, the quantity of which is measured in exhaled breath as a ratio of 13C to 12C.~The nasal or intubated breath sampling investigational device (ID) circuit continuously transports the breath sample from the patient to the BreathID® MCS device before and following administration of the 13C-methylacetanilide test substrate.
Trial: NCT00550212
Drug: neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HKI-272, Single-dose capsule and solution